Dow Jones Industrial Average drops from record as JPMorgan, Visa slide — what Wall Street watches next
13 January 2026
2 mins read

Dow Jones Industrial Average drops from record as JPMorgan, Visa slide — what Wall Street watches next

New York, January 13, 2026, 13:39 EST — Regular session underway.

  • The Dow dipped off Monday’s record high, with bank earnings and rate policy still steering the market.
  • Shares of credit-card lenders and networks fell amid renewed chatter about imposing a rate cap.
  • Traders are eyeing retail sales and producer prices later this week for fresh clues on demand and inflation.

The Dow Jones Industrial Average dropped 0.67% to 49,256.12 on Tuesday, dragged down by financial stocks as investors digested an inflation report that kept the rate-cut discussion open. U.S. crude climbed 2.67% to $61.09 a barrel, with Iran unrest sending oil prices to their highest in weeks. (Reuters)

The benchmark entered the session close to record levels, having just hit an all-time high Monday. Investors shrugged off renewed doubts about the Federal Reserve’s independence. Peter Cardillo, chief market economist at Spartan Capital Securities, noted that “the market is taking it in stride” as earnings season kicks off. (Reuters)

The Labor Department reported consumer prices climbed 0.3% in December, pushing the annual increase to 2.7%, driven mainly by rising shelter and food expenses. Core CPI, which excludes volatile food and energy sectors, rose 0.2% for the month and 2.6% over the past year. Sung Won Sohn of Loyola Marymount University noted that shoppers quickly feel the pinch from higher grocery and restaurant bills. (Reuters)

Visa dropped 4.7%, and Mastercard tumbled 5.3% after JPMorgan Chase CFO Jeremy Barnum’s comments reignited concerns about a potential cap on credit-card interest rates. JPMorgan itself slid 2.5%. Delta Air Lines slipped 2.4% following a weak profit outlook for 2026. Meanwhile, Intel and AMD climbed roughly 5.5% each after KeyBanc upgraded both to “overweight,” signaling optimism for their performance. Ryan Detrick, chief market strategist at Carson Group, pointed out that “the lifeblood of a bull market is rotation,” as futures continued to price in at least two quarter-point rate cuts later this year, according to LSEG data. (Reuters)

The Washington angle is making a comeback in daily trading. A crackdown on card rates threatens a business built on hefty interest income. Traders are scrambling to figure out who will tighten lending first—and how quickly consumers will feel the pinch.

The Dow’s price-weighted setup often amplifies its swings. Large moves in just a few high-priced stocks can overshadow calmer trends in the rest of the index.

Some cash is just hunting for shelter. Energy gets a lift when oil spikes, while staples quietly hold their ground as traders brace for potentially tricky headlines.

But the downside scenario is straightforward. Data remain erratic following shutdown disruptions, tariffs continue to cloud pricing decisions, and earnings guidance can turn negative fast when CEOs shift focus from past quarters to the upcoming one.

Attention now shifts beyond today’s data to upcoming key reports. Investors are set to eye the Census Bureau’s monthly retail trade figures, dropping Wednesday at 8:30 a.m. ET, followed by the Labor Department’s producer price index on Thursday. All eyes will also be on the Fed’s Jan. 27-28 policy meeting for any sign of a change in stance. (Census)

Stock Market Today

  • ABBV inks drug pricing deal with Trump, joins PD-1xVEGF bandwagon
    January 13, 2026, 2:32 PM EST. AbbVie said it signed a U.S. pricing agreement with the Trump administration to cut list prices to match those in comparable developed markets, backing the MFN proposal. The deal includes a three-year exemption from import tariffs on pharmaceutical ingredients if AbbVie expands U.S. manufacturing, and a pledge to invest $100 billion over the next decade in domestic R&D and capital. The government says 16 of 17 large drugmakers have reached similar accords; Regeneron remains in talks. In a separate release, AbbVie agreed to an exclusive license with RemeGen for its PD-1xVEGF bispecific, RC148. AbbVie will pay an upfront $650 million and up to $4.95 billion in milestones, plus royalties, for rights outside Greater China. RC148 is in phase II in China, with potential in NSCLC and CRC. Competitors include Summit, BioNTech/Bristol Myers, Merck and Pfizer pursuing PD-1/VEGF programs.
Seadrill Limited stock jumps 7% as oil rally blunts Citi downgrade
Previous Story

Seadrill Limited stock jumps 7% as oil rally blunts Citi downgrade

EOSE stock jumps nearly 10% as Eos tees up a Jan. 14 update — what investors are watching
Next Story

EOSE stock jumps nearly 10% as Eos tees up a Jan. 14 update — what investors are watching

Go toTop